Header Logo

Connection

Yuki Kageyama to Carcinoma in Situ

Back to Details
This is a "connection" page, showing publications Yuki Kageyama has written about Carcinoma in Situ.
Yuki Kageyama
Connection Strength
0.907
Carcinoma in Situ
  1. Immunostaining for polycomb group protein EZH2 as a diagnostic tool to differentiate urothelial carcinoma in situ from benign lesions. Hum Pathol. 2025 Jun; 160:105823.
    View in: PubMed
    Score: 0.907
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.